Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2001 5
2002 9
2003 2
2004 5
2005 2
2006 3
2007 9
2008 11
2009 8
2010 8
2011 12
2012 10
2013 9
2014 14
2015 11
2016 29
2017 14
2018 11
2019 17
2020 17
2021 13
2022 12
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

216 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab-Induced Cardiomyopathy.
Barish R, Gates E, Barac A. Barish R, et al. Cardiol Clin. 2019 Nov;37(4):407-418. doi: 10.1016/j.ccl.2019.07.005. Epub 2019 Aug 27. Cardiol Clin. 2019. PMID: 31587782 Review.
Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). ...This article summarizes the role of trastuzumab in cancer treatment, the mechanisms of trastuzumab-induced cardiotoxicity, recent clinical investigations, and current controversies... …
Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). ...This article summarizes the role of trastuzumab in …
Drug-induced mitochondrial dysfunction and cardiotoxicity.
Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Varga ZV, et al. Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18. Am J Physiol Heart Circ Physiol. 2015. PMID: 26386112 Free PMC article. Review.
Cardiotoxic agents affecting mitochondria include several widely used anticancer drugs [anthracyclines (Doxorubicin/Adriamycin), cisplatin, trastuzumab (Herceptin), arsenic trioxide (Trisenox), mitoxantrone (Novantrone), imatinib (Gleevec), bevacizumab (Avastin), sunitinib …
Cardiotoxic agents affecting mitochondria include several widely used anticancer drugs [anthracyclines (Doxorubicin/Adriamycin), cisplatin, …
Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells.
Sun L, Wang H, Yu S, Zhang L, Jiang J, Zhou Q. Sun L, et al. Int J Mol Med. 2022 Feb;49(2):17. doi: 10.3892/ijmm.2021.5072. Epub 2021 Dec 22. Int J Mol Med. 2022. PMID: 34935058 Free PMC article.
Ferroptosis has been previously implicated in the pathological progression of cardiomyopathy. Herceptin (trastuzumab), which targets HER2, is commonly applied for the treatment of HER2(+) breast cancer. ...Collectively, these findings provided insights into the path …
Ferroptosis has been previously implicated in the pathological progression of cardiomyopathy. Herceptin (trastuzumab), which t …
Mechanisms of toxic cardiomyopathy.
Hantson P. Hantson P. Clin Toxicol (Phila). 2019 Jan;57(1):1-9. doi: 10.1080/15563650.2018.1497172. Epub 2018 Sep 27. Clin Toxicol (Phila). 2019. PMID: 30260248 Review.
BACKGROUND: Dilated cardiomyopathy is a frequent disease responsible for 40-50% of cases of heart failure. Idiopathic cardiomyopathy is a primary disorder often related to familial/genetic predisposition. ...
BACKGROUND: Dilated cardiomyopathy is a frequent disease responsible for 40-50% of cases of heart failure. Idiopathic cardiomyopat …
Trastuzumab-Induced Cardiomyopathy and Intermittent Left Bundle Branch Block.
Tahir H, Bardia N, Bath K, Ahmed Y, Rafique M, Omar B, Malozzi C. Tahir H, et al. Cardiol Res. 2019 Aug;10(4):230-235. doi: 10.14740/cr888. Epub 2019 Jul 31. Cardiol Res. 2019. PMID: 31413780 Free PMC article.
Trastuzumab-induced cardiomyopathy is a known complication of its use in breast cancer treatment, but it remains mostly asymptomatic and often reversible. ...We report a case of a 52-year-old female breast cancer patient with trastuzumab-induced asymptomatic …
Trastuzumab-induced cardiomyopathy is a known complication of its use in breast cancer treatment, but it remains mostly asympt …
Trastuzumab-induced cardiomyopathy.
Guglin M, Cutro R, Mishkin JD. Guglin M, et al. J Card Fail. 2008 Jun;14(5):437-44. doi: 10.1016/j.cardfail.2008.02.002. J Card Fail. 2008. PMID: 18514938 Review.
Trastuzumab is a recombinant humanized monoclonal antibody used for the treatment of advanced breast cancer. ...Although reversible in most cases, cardiotoxicity frequently results in the discontinuation of trastuzumab. The objective of this review is to summarize f …
Trastuzumab is a recombinant humanized monoclonal antibody used for the treatment of advanced breast cancer. ...Although reversible i …
Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population.
Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KH, Gottlieb SS. Baron KB, et al. J Card Fail. 2014 Aug;20(8):555-9. doi: 10.1016/j.cardfail.2014.05.012. Epub 2014 Jun 4. J Card Fail. 2014. PMID: 24905295

There were no differences in comorbidities, earlier treatment, or demographics between patients with and without trastuzumab-induced cardiomyopathy except that African Americans were more likely to develop decreased LVEF (P < .05). ...LVEF improved in most patien

…
There were no differences in comorbidities, earlier treatment, or demographics between patients with and without trastuzumab-induced …
Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, Shi Z, Laurent CA, Lee VS, Roh JM, Santiago-Torres M, Shen H, Hershman DL, Kushi LH, Neugebauer R, Kwan ML. Greenlee H, et al. J Clin Oncol. 2022 May 20;40(15):1647-1658. doi: 10.1200/JCO.21.01736. Epub 2022 Apr 6. J Clin Oncol. 2022. PMID: 35385342

Over a 7-year average follow-up (range < 1-14 years), women who received anthracyclines and/or trastuzumab had high risk of heart failure/cardiomyopathy relative to controls, with the highest risk seen in women who received both anthracyclines and trastuzumab

…

Over a 7-year average follow-up (range < 1-14 years), women who received anthracyclines and/or trastuzumab had high risk of heart

…
[Biochemical predictors of anthracyclin and trastuzumab induced cardiotoxicity in early diagnostics of cardiomyopathy].
Słowik A, Lelakowska-Pieła M, Konduracka E. Słowik A, et al. Pol Merkur Lekarski. 2016 Jan;40(235):40-5. Pol Merkur Lekarski. 2016. PMID: 26891436 Review. Polish.
The treatment based on athracyclines and trastuzumab may lead to heart failure in oncological setting. Assessment of the heart function is conducted using radiological examinations, especially echocardiography. ...Trials involving mikro RNA particles, which depict the mole …
The treatment based on athracyclines and trastuzumab may lead to heart failure in oncological setting. Assessment of the heart functi …
Protective Effects of Statin and Angiotensin Receptor Blocker in a Rat Model of Doxorubicin- and Trastuzumab-Induced Cardiomyopathy.
Cho DH, Lim IR, Kim JH, Kim MN, Kim YH, Park KH, Park SM, Shim WJ. Cho DH, et al. J Am Soc Echocardiogr. 2020 Oct;33(10):1253-1263. doi: 10.1016/j.echo.2020.05.021. Epub 2020 Aug 7. J Am Soc Echocardiogr. 2020. PMID: 32778498
We investigated the protective effects of rosuvastatin and candesartan, alone and in combination, in a doxorubicin- and trastuzumab-induced rat model of cardiomyopathy. METHODS: Forty-two rats were allocated into six groups (G1-G6): G1, control; G2, doxorubicin only …
We investigated the protective effects of rosuvastatin and candesartan, alone and in combination, in a doxorubicin- and trastuzumab-i …
216 results